INS and type 2 diabetes mellitus: The combination of DAPA + SAXA in insulin-naive patients with poorly controlled T2DM provided similar glycemic control, a lower risk of hypoglycemia, and a meaningful reduction in body weight compared to basal insulin (p<0.0001).